Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
2.796
+0.066 (2.42%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
Scienture Holdings, Inc. operates as health services IT company.
It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, hospitals, clinics, and independent pharmacies.
Scienture Holdings, Inc. is headquartered in Tampa, Florida.
Scienture Holdings, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 13, 2020 |
| Industry | Pharmaceutical Retailers |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Surendra Ajjarapu |
Contact Details
Address: 6308 Benjamin Rd, Suite 708 Tampa, Florida 33634 United States | |
| Phone | 800 261 0281 |
| Website | scienture.com |
Stock Details
| Ticker Symbol | SCNX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001382574 |
| ISIN Number | US80880X1046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Surendra K. Ajjarapu | Chairman of the Board, Chief Executive Officer and Secretary |
| Prashant Patel R.Ph. | Interim Chief Financial Officer, President and Chief Operating Officer |
| Rahul Surana M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer of Scienture LLC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 18, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 14, 2025 | EFFECT | Notice of Effectiveness |
| Feb 6, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 30, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 27, 2025 | DEF 14A | Other definitive proxy statements |
| Jan 17, 2025 | 8-K | Current Report |
| Jan 14, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 8, 2025 | 8-K | Current Report |
| Dec 30, 2024 | DEF 14C | Filing |
| Dec 20, 2024 | PRE 14C | Filing |